M.S. in Biomedical Innovation and Development – Advanced Therapeutics
The MSBID-AT program at Emory University is a full-time, 12-month professional master’s degree designed to prepare students for impactful careers in the rapidly growing field of advanced therapeutics. Unlike traditional programs in drug discovery or vaccine development, MSBID-AT focuses on emerging industries such as cell therapy, gene therapy, tissue engineering, and regenerative medicine. Students gain hands-on experience at the intersection of science, healthcare, and business—ready to translate innovation from lab to bedside.

Program Details
- 12-month full-time program (Fall, Spring, Summer)
- Full-time, residential
- No thesis required
- Based at Emory University
- Total: 36 credit hours (including core courses and electives)
The Advanced Therapeutics track provides focused learning in:
- Gene Therapy
- Regenerative Medicine
- Targeted Drug Delivery
- Biologics and Cell-Based Therapies
- Develop cutting-edge therapies from concept through preclinical translation.
- Engage in team-based capstone projects with real-world clinical applications.
The MSBID-AT curriculum is designed to cover the full lifecycle of advanced therapeutic development—from identifying unmet clinical needs to commercialization. Students work in teams to identify a real-world clinical challenge, propose a therapeutic solution, and develop a commercialization strategy including regulatory and reimbursement pathways.
Fall Term (11 credit hours total) | |
---|---|
Understanding the Global Therapeutics Market | 2 credit hours |
Introduction to Emerging Technologies in Advanced Therapeutics | 2 credit hours |
Preclinical Product and Process Development | 3 credit hours |
Global Clinical Strategy and Clinical Operations | 2 credit hours |
Medical Ethics, Medical Affairs, and Clinical Communication | 2 credit hours |
Spring Term (10 credit hours total) | |
---|---|
Clinical and Commercial Scale Manufacturing Strategies | 3 credit hours |
Regulatory and Quality Affairs | 3 credit hours |
Project Management, Corporate Communication, and Organization in Biotech | 2 credit hours |
MSBID-AT Team Project I | 2 credit hours |
Summer Term (9 credit hours total) | |
---|---|
Corporate Marketing, Intellectual Property and Legal Considerations | 3 credit hours |
Financing and Reimbursement in Biotech | 3 credit hours |
MSBID-AT Team Project II | 3 credit hours |
Total Credit Hours | 30 credit hours |
Course Descriptions
In this course, students will study the breadth of the industry, its structure, markets, specialties, and commercial opportunities. They will be exposed to the initial process of developing a new product which starts with uncovering unmet clinical needs.
This course will be an introduction to evolving new advanced therapeutic technologies and cover some of the emerging technologies in the evolving therapeutic space. These include cell therapies, gene therapies, stem cells, genome editing, CRISPR technology, tissue engineering, regenerative biomaterials, and combination therapies. The course will also help the student describe the process of selection of an appropriate new therapeutic product for a given unmet clinical need.
This course will cover an introduction to industry standard methods, techniques and processes for preclinical product and process development for a new therapeutic agent or product. The industry has a well-established process by which desired product attributes meet specific endpoints and are developed. Oftentimes, new processes must be developed for the manufacture of these new modalities of treatment. The student will be exposed to these and other related concepts in new product design and manufacture.
This course will examine the process and ethical considerations that provide for the safe and humane clinical testing of new therapies in a preclinical and clinical setting with human subjects. It will cover topics such as clinical trial design and trial management and operations. It will also review the ties of clinical operations with science based and scientifically bourn marketing claims once approved by the authorized regulator in a given market
This course will explore the different techniques and processes available to manufacture advanced therapeutic products. It is important to recognize that there are different types of cell, gene, and other advanced therapies that face very different manufacturing challenges. Additionally, biologically based and combination advanced therapies face their own processing requirements. Clinical trial design and ultimate commercial distribution goals of a new therapy will be one of the guideposts that determine a manufacturing strategy for a new therapy.
This course will provide an overview of both regulatory and quality aspects of the advanced therapies industry and allow the student to develop an understanding of pathways necessary for proper quality and regulatory compliance. The course will cover key topics such as the role of the patient in the overall regulatory strategy for a new product, the concept of total quality and risk management tools and techniques in the process of the development of new products, and the components of a quality management system.
Successful development and introduction of a new therapeutic agent requires solid mastery of project management and communications skills. This course will review basic project management skills, team leadership skills, and best practices in corporate communication and the ethical considerations therein. Additionally, the student will be introduced to a traditional organizational hierarchy in the biotech industry.
These courses are a two part series, Team Project I and Team Project II. The MSBID-AT team project classes will mimic and involve the real-life process of selecting an underserved disease or unmet clinical need (or cycle of care), propose a solution, build a business case, and address reimbursement and regulatory paths. The final deliverable being the writing and presentation of the Business Report. Team Project Course I will cover items such as defining the unmet clinical need, mapping the regulatory and reimbursement landscape and building the required product specifications. In this two-course series, the groups will do everything through this process except develop a hands-on construct. The training through this curriculum will provide work on real life concepts, real-life experience, integrated project, and team work.
This course will review the background and history of medical ethics in the conduct of human clinical research and use that knowledge as a backdrop to understanding the importance of preclinical research in the development of new clinical therapies. Additionally, the course will review the ethical process of communicating clinical research to the broader clinical community and explore the process of marketing, selling, and clinical communications as a whole.
This course will provide an introduction to front and back end marketing processes, as well as an introduction to intellectual property and corporate law in their role in product development in the biotech industry. Students will be exposed to careers in these fields and opportunities for scientists to take a larger role in professional marketing efforts vis-à-vis traditional product development activities.
This course will expose the students to the importance of the regulatory and reimbursement environment and processes in the development of successful next generation advanced therapies. Understanding of the importance that these two subjects play is critical in the successful launch of a new product. Topics to be covered in this course include the importance of a reimbursement strategy as it affects the product development strategy and an understanding of the general US product reimbursement environment. Additionally, the student will be exposed to standard financial analysis tools that will allow them to explain the process of determining the financial value of a new product in the biotech space.
- Angela Gill Nelms – Managing Director, Biolocity; biotech entrepreneur and commercialization strategist
- Samir Patel, Ph.D. – Co-founder & CEO, Moonlight Therapeutics; expert in drug delivery and startup leadership
- Phillip J. Santangelo, Ph.D. – Professor of Biomedical Engineering; pioneer in nucleic acid-based therapies
- Abbey Wojtowicz, Ph.D. – Medical Director in gastroenterology; specialist in strategic scientific communications
Graduates are equipped for high-impact roles, including:
- Product Development and R&D
- Regenerative Medicine Scientist
- Biologics Process Development Specialist
- Regulatory Affairs Scientist
- Clinical Research Scientist
- Drug Delivery Design Engineer
- Biotechnology Startup
Alumni pursue careers in leading biotech and pharmaceutical companies or continue in translational research and innovation

We're here to help
We’re here to answer your questions and help you take the next step.
Program Contact:
Carolyn Yeago
Director of Graduate Study
cyeago@emory.edu